High prevalence of metabolic syndrome in patients with ankylosing spondylitis. 2007

Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
Unità di Reumatologia, Seconda Università di Napoli, Policlinico Via Pansini 5, 80131 Naples, Italy.

The objective of this work is to investigate the occurrence of atherosclerosis and metabolic syndrome (MetS) in ankylosing spondylitis (AS) patients (pts). Twenty-four consecutive AS pts (men, 87.5%; median age, 50.5 years; median disease duration, 16.5 years), fulfilling the modified 1984 New York criteria for AS criteria, and 19 age- and sex-matched controls were investigated. Clinical atherosclerosis was evaluated by physical examination for cardiovascular (CV) diseases and history or drug use for CV events. Subclinical atherosclerosis was detected by mean intima media thickness (a-IMT) and maximum IMT (max-IMT) of carotid arteries using ultrasonography. Laboratory investigations including fasting plasma glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides were assessed by standard methods, while homocysteine was assessed by chemiluminescence. MetS was assessed using the updated NCEP-ATP III criteria. Disease activity was defined according to the International Ankylosing Spondylitis Assessment Study criteria. The 10-year CV risk (%) profile was evaluated in agreement to the Progetto Cuore criteria. No major CV event was detected in the study population. No significant differences were found when AS pts and controls were compared according to the mean a-IMT (0.52+/-0.26 vs 0.51+/-0.13 mm), max-IMT (0.92+/-0.20 vs 0.85+/-0.39 mm), prevalence of abnormal max-IMT >1 mm (27.2 vs 5.3%), and 10-year CV risk (9.9+/-9.6 vs 3.6+/-1.8%). Systolic blood pressure (p=0.04), triglyceride to HDL cholesterol ratio (p=0.002), and LDL cholesterol (p=0.03) were found significantly higher in AS pts than in controls; on the contrary, HDL cholesterol was pointed out as significantly lower (p<0.001). MetS was found in 11/24 (45.8%) AS pts and in 2/19 (10.5%) controls (p=0.019). No significant relationship emerged in MetS prevalence among AS pts regarding the mean value of age, disease duration, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index, and the Italian version of Health Assessment Questionnaire. This preliminary report points out a higher prevalence of MetS in AS pts than in controls. Further studies are needed to confirm this finding.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013167 Spondylitis, Ankylosing A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions. Ankylosing Spondylitis,Bechterew Disease,Marie-Struempell Disease,Rheumatoid Spondylitis,Spondylarthritis Ankylopoietica,Ankylosing Spondylarthritis,Ankylosing Spondyloarthritis,Bechterew's Disease,Spondylitis Ankylopoietica,Spondyloarthritis Ankylopoietica,Ankylosing Spondylarthritides,Ankylosing Spondyloarthritides,Bechterews Disease,Marie Struempell Disease,Spondylarthritides, Ankylosing,Spondylarthritis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
January 2019, Diabetes, metabolic syndrome and obesity : targets and therapy,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
January 2019, Diabetes, metabolic syndrome and obesity : targets and therapy,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
July 2018, Joint bone spine,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
February 2007, Clinical rheumatology,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
August 1993, The Journal of rheumatology,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
January 2014, BioMed research international,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
April 2009, Rheumatology (Oxford, England),
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
October 1995, The Journal of rheumatology,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
January 2009, Clinical and experimental rheumatology,
Domenico Malesci, and Alferio Niglio, and Gianna Angela Mennillo, and Rosario Buono, and Gabriele Valentini, and Giovanni La Montagna
April 2020, Cytokine,
Copied contents to your clipboard!